William Hodder
Directeur Général chez NFlection Therapeutics, Inc.
Profil
William A.
Hodder was the founder of Trenovus, Inc. founded in 2010, where he served as Chief Executive Officer from 2010 to 2012.
He is currently the President, Chief Executive Officer & Director at NFlection Therapeutics, Inc. since 2021.
Mr. Hodder's former positions include President, Chief Executive Officer & Director at Vapogenix, Inc., Director-Business Development & Marketing at Aradigm Corp.
from 1997 to 2001, Vice President-Business Development at FibroGen, Inc., Vice President-Business Development at Promedior, Inc. from 2013 to 2014, and Senior Vice President-Corporate Development at Protagonist Therapeutics, Inc. Mr. Hodder's education history includes an undergraduate degree from Oakland University (Michigan) and an MBA from The University of Chicago Booth School of Business.
Postes actifs de William Hodder
| Sociétés | Poste | Début |
|---|---|---|
NFlection Therapeutics, Inc.
 NFlection Therapeutics, Inc. BiotechnologyHealth Technology NFlection Therapeutics, Inc. operates as a biotechnology company. It focuses on the development of therapies for Neurofibromatosis. The company was founded by Mark de Souza and Michael Wootton in 2014 and is headquartered in Wayne, PA. | Directeur Général | 18/10/2021 |
Anciens postes connus de William Hodder
| Sociétés | Poste | Fin |
|---|---|---|
Promedior, Inc.
 Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 01/07/2014 |
| Trenovus, Inc. | Directeur Général | 01/01/2012 |
| ARADIGM CORPORATION | Sales & Marketing | 01/01/2001 |
Vapogenix, Inc.
 Vapogenix, Inc. Medical/Nursing ServicesHealth Services Vapogenix, Inc. operates as a clinical stage company which develops a new class of non-narcotic analgesics for localized pain. Its products are formulated volatile anesthetics; currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. The company was founded by Allen W. Burton, Phillip C. Phan and Danguole Spakevicius Altman in November 2007 and is headquartered in Houston, TX. | Directeur Général | - |
| PROTAGONIST THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de William Hodder
| Oakland University (Michigan) | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| PROTAGONIST THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Aradigm Corp.
 Aradigm Corp. Pharmaceuticals: MajorHealth Technology Aradigm Corp. was a pharmaceutical company, which was focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. The company was founded in 1991 and was headquartered in Hayward, CA. | Health Technology |
Vapogenix, Inc.
Vapogenix, Inc. Medical/Nursing ServicesHealth Services Vapogenix, Inc. operates as a clinical stage company which develops a new class of non-narcotic analgesics for localized pain. Its products are formulated volatile anesthetics; currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. The company was founded by Allen W. Burton, Phillip C. Phan and Danguole Spakevicius Altman in November 2007 and is headquartered in Houston, TX. | Health Services |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Health Technology |
| Trenovus, Inc. | |
NFlection Therapeutics, Inc.
NFlection Therapeutics, Inc. BiotechnologyHealth Technology NFlection Therapeutics, Inc. operates as a biotechnology company. It focuses on the development of therapies for Neurofibromatosis. The company was founded by Mark de Souza and Michael Wootton in 2014 and is headquartered in Wayne, PA. | Health Technology |
